Try our beta test site
20 studies found for:    Open Studies | Anaplastic Large Cell | Phase 1
Show Display Options
Rank Status Study
1 Recruiting Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Conditions: Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: questionnaire administration
2 Not yet recruiting Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive;   Systemic Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Ceritinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
3 Recruiting Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
Conditions: Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Bendamustine;   Drug: Neulasta
4 Recruiting Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Condition: ALK+ Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab vedotin;   Drug: Imatinib
5 Recruiting Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Conditions: Peripheral T-cell Lymphomas (PTCL);   PTCL-NOS;   Angioimmunoblastic T-cell Lymphoma (AITL);   ALK- Anaplastic Large Cell Lymphoma (ALCL)
Interventions: Drug: Ro-CHOEP-21 (PHASE I);   Drug: Ro-CHOEP-21 (PHASE II)
6 Recruiting A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Non-Small Cell Lung Cancer (ALK-positive);   Non-Small Cell Lung Cancer (c-Met Dependent);   Non-Small Cell Lung Cancer (ROS Marker Positive);   Systemic Anaplastic Large-Cell Lymphoma;   Advanced Malignancies (Except Leukemia)
Interventions: Drug: PF-02341066;   Drug: Rifampin;   Drug: Itraconazole
7 Recruiting Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Condition: Anaplastic Lymphoma Kinase (ALK)
Intervention: Drug: LDK378
8 Not yet recruiting VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma
Conditions: Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Angioimmunoblastic T-cell Lymphoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Plasma Cell Myeloma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Angioimmunoblastic T-cell Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Refractory Plasma Cell Myeloma;   Refractory T-Cell Non-Hodgkin Lymphoma
Interventions: Biological: Biological Therapy;   Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Single Photon Emission Computed Tomography
9 Recruiting Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Hepatosplenic T-Cell Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Stage II Angioimmunoblastic T-cell Lymphoma;   Stage II Enteropathy-Associated T-Cell Lymphoma;   Stage III Angioimmunoblastic T-cell Lymphoma;   Stage III Enteropathy-Associated T-Cell Lymphoma;   Stage IV Angioimmunoblastic T-cell Lymphoma;   Stage IV Enteropathy-Associated T-Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Etoposide;   Drug: Prednisone;   Drug: Lenalidomide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
10 Recruiting CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Lymphocyte Predominant Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia
Interventions: Drug: 6,8-bis(benzylthio)octanoic acid;   Drug: bendamustine hydrochloride
11 Recruiting Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Burkitt Lymphoma;   Diffuse Large Cell Lymphoma;   Gray Zone Lymphoma;   Lymphoblastic Lymphoma;   Anaplastic Large Cell Lymphoma;   Hodgkin Lymphoma
Intervention: Drug: CPX-351
12 Recruiting Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Epstein-Barr Virus Infection;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: brentuximab vedotin;   Biological: rituximab;   Other: laboratory biomarker analysis
13 Recruiting CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
Condition: Lymphomas
Intervention: Genetic: Anti-CD30 CAR T cells
14 Recruiting Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Nonmalignant Neoplasm
Interventions: Other: biologic sample preservation procedure;   Other: cytology specimen collection procedure
15 Recruiting 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Conditions: Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Device: 3'-deoxy-3'-[18F]fluorothymidine
16 Recruiting Registry of Older Patients With Cancer
Conditions: Chronic Myeloproliferative Disorders;   Cognitive/Functional Effects;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:
17 Recruiting Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Multiple;   Mycosis Fungoides;   Hodgkin's Lymphoma;   Multiple Myeloma
Intervention: Drug: Dasatinib
18 Recruiting Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Myeloid Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome;   Lymphoid Leukemia
Interventions: Drug: Dasatinib;   Other: laboratory biomarker analysis
19 Recruiting Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Conditions: Lymphoid Malignancies;   Multiple Myeloma;   Lymphoma;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma
Interventions: Drug: Pralatrexate;   Drug: Romidepsin
20 Recruiting Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Conditions: Lymphoid Malignancies;   Lymphoma;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma
Interventions: Drug: Romidepsin;   Drug: Oral 5-Azacitidine

Study has passed its completion date and status has not been verified in more than two years.